Title: Detection of Extended Spectrum Beta-Lactamases in Pseudomonas aeruginosa Isolates in a Tertiary Care Hospital
Authors: P R Lyra, Sindhu Cugati, K Anuradha, D Venkatesha
DOI: https://dx.doi.org/10.18535/jmscr/v5i4.94
Abstract
Background: Extended spectrum ß-lactamases (ESBLs) represent a major group of lactamases responsible for resistance, mostly produced by gram-negative bacteria, to newer generations of ß-lactam drugs currently being identified in large numbers worldwide. The aim of the present study was to detect the extended-spectrum β-lactamase (ESBL) production among Pseudomonas aeruginosa isolates from various samples.
Materials and Methods: A total of 100 Pseudomonas aeruginosa isolates from various samples in a tertiary care hospital from January 2011 to December 2011 were included in the study. Kirby-Bauer’s disc diffusion method was employed to detect the antibiotic susceptibility pattern of the isolates. The isolates were tested for ESBL production using double-disc synergy test (DDST) using ceftazidime alone and combined ceftazidime- clavulanic acid discs.
Result: Out of the 100 Pseudomonas aeruginosa isolates studied, 45 (45%) were ESBL producers .Out of the ESBL producing isolates, 44 (98%) were resistant to third generation cephalosporins, 28 (62%) to Ciprofloxacin ,34(76 %) to Gentamicin, 28(62%) to Amikacin respectively. 45(100%) of isolates were susceptible to Imipenem.
Conclusion: This study emphasizes on the need for global control of antimicrobial resistance; and to create awareness among the clinicians and general population thereby reducing the mortality and morbidity associated with multi-drug resistant pathogens.
Keywords: Pseudomonas aeruginosa, extended spectrum β-lactamases, third-generation cephalosporins, Kirby-Bauer disc diffusion technique, double-disc synergy test, Multidrug Resistance.
References
1. Winn W, Allen S, Janda W, Koneman F, Procop G et al. Color Atlas and textbook of diagnostic microbiology. 6thed. Lippincott Williams and Wilkins 2006; 318-320.
2. Ibukun A, Tochukwu N, Tolu O. Occurrence of ESBL and MBL in clinical isolates of Pseudomonas aeruginosa from Lagos, Nigeria. Journal of American Science 2007; 3(4): 81-85.
3. Collee J.G., Fraser A.G., Marmion B.P., Simmons A.: Mackie and McCartney Prac-tical Medical Microbiology, 14th edition. Churchill Livingstone, New York, 1996.
4. Ana Lucia Peixoto de Freitas and Afonso Luis Barth. Antibiotic resistance and mole-cular typing of Pseudomonas aeruginosa: Focus on Imipenem. The Brazilian Journal of Infectious Diseases.2002;6(1):1-7.
5. Gamal FG, Ramadan A, El-Domany, Sahar Zakiand, Hossam M.A. Characterization of Pseudomonas aeruginosa isolated from clinical and environmental samples in Minia, Egypt: prevalence, antibiogram and resista-nce mechanisms. Journal of Antimicrobial Chemotherapy 2007; 6: 1010-1017.
6. Poirel L, Naas T, Nicholas D, Collet L, Bellais S, Cavallo JD, et al. Characterization of VIM-2, a Carbapenem-hydrolyzing metallo-betalactamase and its plasmid-and integron-born gene from a Pseudomonas aeruginosa clinical isolate in France. Antim-icrob Agents Chemother.2000; 44:891-97.
7. Naas T, Phiippon L, Poirel L, Ronco E, Nordmann P. An SHVderived extended- spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43: 1281-4.
8. Mugnier P, Dubrous P, Casin I, Arlet G, Collatz E. A TEMderived extended-spectrum β-lactamase in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40:2488-93.
9. Prashant K P, Basvaraj V P. Non-Fermenters in human infections with special reference to Acinetobacter species in a tertiary care hospital from North Karnataka, India. Journal of Krishna Institute of Medical Science University2012; 1(1): 84 -8.
10. Nathisuwan S, Burgess DS, Lewis JS 2nd. Extended-spectrum β-lactamases: Epidemi-ology, detection and treatment. Pharmacotherapy 2001; 21:920-8.